Abbvie-Header Abbvie-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            ALK

            • Development Update

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Short Ragweed Pollen Allergen Extract

            Therapeutic Area: Immunology Product Name: Ragwitek

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 19, 2021

            Details:

            ALK has gained approval from the US Food and Drug Administration, to expand the use of ALK’s ragweed sublingual allergy immunotherapy (SLIT) tablet RAGWITEK® (RAGWIZAX® in Europe) to include paediatric patients, down to the age of 5, with ragweed-induced allergic rhinitis.